SCHEMBL23769693

SCHEMBL23769693

CCOC(=O)c1cc(Cc2ccc(N3CC4CC4C3)nc2)no1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OGA O60502 1/20 0.38
KLKB1 P03952 3/20 0.37
HRH3 Q9Y5N1 1/20 0.36
KMT2A Q03164 1/20 0.36
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35
PIK3CA P42336 1/20 0.35
NMT2 O60551 1/20 0.35
NMT1 P30419 1/20 0.35
P2RY12 Q9H244 1/20 0.35
RET P07949 3/20 0.35
SGPL1 O95470 1/20 0.35
HPGD P15428 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ACACB O00763 1/20 0.34
KLK1 P06870 1/20 0.34
HDAC3 O15379 1/20 0.34
HDAC4 P56524 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC7 Q8WUI4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23769269 0.85 GRM1 (0.37) KLKB1CYP11B1CYP11B2HDAC3HDAC4
SCHEMBL23768922 0.81 KLKB1 (0.41) KLKB1HPGDSMN1; SMN2
SCHEMBL29906637 0.81 KLKB1 (0.41) KLKB1HPGDSMN1; SMN2
SCHEMBL23768910 0.81 KLKB1 (0.41) KLKB1KMT2APIK3CA
SCHEMBL23768964 0.81 KLKB1 (0.41) KLKB1PIK3CA
SCHEMBL23769298 0.81 KLKB1 (0.41) KLKB1KMT2APIK3CA
SCHEMBL23769404 0.79 KLKB1 (0.40) KLKB1PIK3CAHPGDHDAC4HDAC6
SCHEMBL23769304 0.76 KLKB1 (0.39) KLKB1KMT2AHPGD
SCHEMBL30739080 0.75 LMNA (0.45) KLKB1KMT2AHPGDSMN1; SMN2HDAC4
SCHEMBL21736670 0.74 KLKB1 (0.56) KLKB1KMT2AP2RY12RETHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11760745-B2 Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-09-19 US disclosed
US-11760745-B2 Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-09-19 US disclosed
US-20210292301-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2021-09-23 US disclosed
WO-2021160718-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2021-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210292301-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 OGA 1937/4885KLKB1 1/4885HRH3 69/4885
US-11760745-B2 Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors KLKB1, KLK5, KLK1 OGA 1937/4885KLKB1 1/4885HRH3 69/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.